amantadine has been researched along with Athletic Injuries in 3 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Athletic Injuries: Injuries incurred during participation in competitive or non-competitive sports.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine was the most commonly prescribed medication, with amitriptyline and melatonin also being prescribed." | 1.46 | Predictors of Pharmacological Intervention in Adolescents With Protracted Symptoms After Sports-Related Concussion. ( Henry, LC; Pinto, SM; Twichell, MF, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moran, B | 1 |
| Tadikonda, P | 1 |
| Sneed, KB | 1 |
| Hummel, M | 1 |
| Guiteau, S | 1 |
| Coris, EE | 1 |
| Pinto, SM | 1 |
| Twichell, MF | 1 |
| Henry, LC | 1 |
| Meehan, WP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury[NCT02383472] | 53 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs color-word interferences, made up of color naming, word reading, and inhibition, is measured in seconds, a smaller number represents a better outcome. Participants were given 90 seconds to complete color naming and word reading and 180 seconds to complete inhibition. D-KEFs trail making test, made up of number sequencing, letter sequencing, and number-letter sequencing, is measured in seconds, a faster speed (lower number) represents a better outcome. Participants were given 150 seconds to complete number and letter sequencing and 240 seconds to complete number-letter sequencing. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Seconds (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D-KEFs Color Naming - 3 Weeks | D-KEFs Color Naming - 6 Weeks | D-KEFs Word Reading - 3 Weeks | D-KEFs Word Reading - 6 Weeks | D-KEFs Inhibition - 3 Weeks | D-KEFs Inhibition - 6 Weeks | D-KEFs Number Sequencing - 3 weeks | D-KEFs Letter Sequencing- 3 weeks | D-KEFs Number-Letter Sequencing- 3 weeks | D-KEFs Number Sequencing - 6 weeks | D-KEFs Letter Sequencing- 6 weeks | D-KEFs Number-Letter Sequencing- 6 weeks | |
| MedX Health Console Model 1100 | 3.27 | 3.76 | 0.95 | 1.71 | 7.64 | 32.62 | -24.45 | -28.41 | 8.00 | 11.33 | 6.86 | 12.95 |
| MedX Health Console Model 1100-placebo | 4.76 | 4.07 | 4.07 | 3.44 | 4.48 | 31.59 | -21.17 | -19.51 | 21.93 | 6.89 | 10.59 | 19.81 |
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs Verbal Fluency Test, made up of letter fluency and category fluency, is measured by number of responses, a larger number represents a better outcome. Participants were given 60 seconds to complete each fluency test. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Correct responses (Mean) | |||
|---|---|---|---|---|
| D-KEFs Verbal Fluency- letters 3 weeks | D-KEFs Verbal Fluency- letters 6 weeks | D-KEFs Verbal Fluency- category 3 weeks | D-KEFs Verbal Fluency- category 6 weeks | |
| MedX Health Console Model 1100 | -3.45 | -6.71 | -1.14 | -1.62 |
| MedX Health Console Model 1100-placebo | -6.10 | -9.89 | -0.03 | -2.00 |
The primary outcome is mean difference on composite scores of Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) between entry into the study and completion of treatment (visit 18, week 6) for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 6 week scores. There are 5 composite scores on the ImPACT test; verbal memory, visual memory, visual motor speed, reaction time, and symptom score. The ranges for these subscales are as follows: verbal memory and visual memory: 0-100, visual motor speed: 0-60, reaction time: 0-1.0, and symptom score: 0-132. A higher verbal memory, visual memory, and visual motor speed represent a better outcome, while a lower reaction time and lower symptom score represent a better outcome. (NCT02383472)
Timeframe: From baseline to 6 weeks
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Verbal Memory | Visual Memory | Visual Motor Speed | Reaction Time | Symptom Score | |
| MedX Health Console Model 1100 | -0.9 | 3.52 | -2.04 | -0.001 | 10.14 |
| MedX Health Console Model 1100-placebo | -5.78 | -7.26 | -5.15 | 0.030 | 11.44 |
"This measure indicates the mean difference in total cognitive symptom scores between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 weeks scores. The total cognitive symptom scored is a sum of 7 symptom scores from the PCSS; feeling slowed down, feeling like in a fog, don't feel right, difficulty concentrating, difficulty remembering, fatigue or low energy, and confusion. The severity of these symptoms are scored 0-6, 0=none, 6=severe. The range for the total cognitive symptom score is 0-42, a lower score represents a better outcome." (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Sx Score - 3 Weeks | Cognitive Sx Score - 6 Weeks | |
| MedX Health Console Model 1100 | 3.95 | 4.00 |
| MedX Health Console Model 1100-placebo | 1.31 | 5.00 |
This measure indicates the mean differences in total post concussion symptom score (PCSS) between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. The PCSS is a sum of severity scores from 0-6 (0=none, 6=severe) for 22 individual symptoms, like headache, neck pain, or drowsiness. The range for the PCSS is 0-132, a lower score represents a better outcome. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| PCSS Total Score - 3 Weeks | PCSS Total score - 6 Weeks | |
| MedX Health Console Model 1100 | 9.41 | 7.86 |
| MedX Health Console Model 1100-placebo | 7.03 | 14.63 |
2 reviews available for amantadine and Athletic Injuries
| Article | Year |
|---|---|
Postconcussive Syndrome Following Sports-related Concussion: A Treatment Overview for Primary Care Physicians.
Topics: Amantadine; Antidepressive Agents; Athletic Injuries; Cognitive Behavioral Therapy; Dopamine Agents; | 2015 |
Medical therapies for concussion.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Athletic Injuries; Brain Concussion; Bra | 2011 |
1 other study available for amantadine and Athletic Injuries
| Article | Year |
|---|---|
Predictors of Pharmacological Intervention in Adolescents With Protracted Symptoms After Sports-Related Concussion.
Topics: Adolescent; Amantadine; Anticonvulsants; Athletic Injuries; Brain Concussion; Cohort Studies; Female | 2017 |